Track topics on Twitter Track topics that are important to you
Tremfya hit the mark in two late-stage psoriatic arthritis trials, setting the stage for another potential approval.
Original Article: Janssen Eyes Another Approval for Tremfya After Hitting Trial EndpointsNEXT ARTICLE
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....